The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
Abstract
Purpose: To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. Methods: For the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and Conclusions: Thirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“and overall survival when combined with chemotherapy compared with chemotherapy alone in the metastatic setting.(95) Phase II mono-”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Sotiriou, C., Wirapati, P., Loi, S., Harris, A., Fox, S., Smeds, J., Nordgren, H., Farmer, P., Praz, V., Haibe-Kains, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj052 · Cited by 2,063
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Self-citationHaagenson, C. (1971) · Cited by 1,773
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
Perou, C. M., Jeffrey, S. S., van de Rijn, M., Rees, C. A., Eisen, M. B., Ross, D. T., Pergamenschikov, A., Williams, C. F., Zhu, S. X., Lee, J. C. F., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9212 · Cited by 1,402
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Self-citationA Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
Predicting the clinical status of human breast cancer by using gene expression profiles
West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Marks, J. R., & Nevins, J. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201162998 · Cited by 1,318
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N., & Szallasi, Z. (2006) · Nature Genetics · doi:10.1038/ng1861 · Cited by 1,193
Self-citationBuzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Self-citationAmplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma
King, C. R., Kraus, M. H., & Aaronson, S. A. (1985) · Science · doi:10.1126/science.2992089 · Cited by 1,072
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
Self-citationerb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,010
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., & Chan, D. W. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1296 · Cited by 893
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
Fisher, B., Costantino, J., Redmond, C., Fisher, E., Margolese, R., Dimitrov, N., Wolmark, N., Wickerham, D. L., Deutsch, M., Ore, L., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306033282201 · Cited by 827
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779
Self-citationCirculating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E., Miller, M. C., Matera, J., Repollet, M., Doyle, G. V., Terstappen, L. W. M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1769 · Cited by 775
Self-citationTumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Self-citationPrognostic classification of breast ductal carcinoma-in-situ
Poller, D. N., Barth, A., Slamon, D. J., Silverstein, M. J., Gierson, E. D., Coburn, W. J., Waisman, J. R., Gamagami, P., & Lewinsky, B. S. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90982-6 · Cited by 679
The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the Breast
Silverstein, M. J., Lagios, M. D., Groshen, S., Waisman, J. R., Lewinsky, B. S., Martino, S., Gamagami, P., & Colburn, W. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401902 · Cited by 673
Gruvberger-Saal, S. K., Ringnér, M., Chen, Y., Panavally, S., Saal, L. H., Borg, Å., Fernö, M., Peterson, C., & Meltzer, P. S. (2001) · PubMed · Cited by 673
Incidence of and Treatment for Ductal Carcinoma In Situ of the Breast
Ernster, V. L. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530360023033 · Cited by 626
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 626
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Houghton, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13859-7 · Cited by 599
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596
Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., & King, C. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.1.103 · Cited by 594
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
Autoantibody Signatures in Prostate Cancer
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051931 · Cited by 582
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Self-citationCyclin E and Survival in Patients with Breast Cancer
Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021153 · Cited by 557
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
Cronin, M., Pho, M., Dutta, D., Stephans, J. C., Shak, S., Kiefer, M. C., Esteban, J. M., & Baker, J. B. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63093-3 · Cited by 551
Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., Halberg, F., Somerfield, M. R., & Davidson, N. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8575 · Cited by 535
Self-citationFISHER, B. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90133-2 · Cited by 516
Cyclin E in normal and neoplastic cell cycles
Hwang, H. C., & Clurman, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208613 · Cited by 514
Julien, J.-P., Bijker, N., Fentiman, I. S., Peterse, J. L., Delledonne, V., Rouanet, P., Avril, A., Sylvester, R., Mignolet, F., Bartelink, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06341-2 · Cited by 514
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Rules of evidence for cancer molecular-marker discovery and validation
Ransohoff, D. F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1322 · Cited by 498
Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., Kaul, S., & Bastert, G. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.22.1652 · Cited by 477
Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., & Eudey, L. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.599 · Cited by 456
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1340 · Cited by 441
Cote, R. J., Rosen, P. P., Lesser, M. L., Old, L. J., & Osborne, M. P. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1749 · Cited by 435
Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H.-K., Graeff, H., & Schmitt, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.913 · Cited by 434
Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2702 · Cited by 407
Braun, S., Kentenich, C., Janni, W., Hepp, F., de Waal, J., Willgeroth, F., Sommer, H., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394
Järvinen, T. A. H., Tanner, M., Rantanen, V., Bärlund, M., Borg, Å., Grénman, S., & Isola, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64952-8 · Cited by 387
Ductal Carcinoma In Situ, Complexities and Challenges
Leonard, G. D., & Swain, S. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh164 · Cited by 386
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Foekens, J. A., Atkins, D., Zhang, Y., Sweep, F. C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A. M., Talantov, D., Span, P. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9115 · Cited by 361
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Burstein, H. J., Harris, L. N., Marcom, P. K., Lambert-Falls, R., Havlin, K., Overmoyer, B., Friedlander, R. J., Gargiulo, J., Strenger, R., Vogel, C. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.018 · Cited by 342
Self-citationTumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations
Molina, R., Barak, V., van Dalen, A., Duffy, M. J., Einarsson, R., Gion, M., Goike, H., Lamerz, R., Nap, M., Sölétormos, G., et al. (2005) · Tumor Biology · doi:10.1159/000089260 · Cited by 334
Knoop, A. S., Knudsen, H., Balslev, E., Rasmussen, B. B., Overgaard, J., Nielsen, K. V., Schonau, A., Gunnarsdóttir, K., Olsen, K. E., Mouridsen, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.007 · Cited by 320
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes, D. F., Zurawski, V. R., & Kufe, D. W. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1542 · Cited by 319
Self-citationSomatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
Colozza, M., Azambuja, E., Cardoso, F., Sotiriou, C., Larsimont, D., & Piccart, M. J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi352 · Cited by 307
Paik, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.1991 · Cited by 304
Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 296
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study
Mansi, J. L., Gogas, H., Biss, J. M., Gazet, J.-C., Berger, U., & Coombes, R. C. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10175-7 · Cited by 295
Duct Carcinoma in Situ: Pathology and Treatment
Lagios, M. D. (1990) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)45185-6 · Cited by 290
Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., Ashley, S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.559 · Cited by 288
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report
Duffy, M. J., O'siorain, L., O'grady, P., Devaney, D., Fennelly, J. J., & Lijnen, H. J. (1988) · Cancer · doi:10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b · Cited by 282
Burstein, H. J., Harris, L. N., Gelman, R., Lester, S. C., Nunes, R. A., Kaelin, C. M., Parker, L. M., Ellisen, L. W., Kuter, I., Gadd, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.124 · Cited by 280
Self-citationLeo, A. D., Gancberg, D., Larsimont, D., Tanner, M., Järvinen, T. A. H., Rouas, G., Dolci, S., Leroy, J.-Y., Paesmans, M., Isola, J. J., et al. (2002) · PubMed · Cited by 267
Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis
Boyages M.B.B.S., J., Delaney M.B.B.S., G., & Taylor M.B.B.S., R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<616::aid-cncr12>3.0.co;2-7 · Cited by 264
Xenidis, N., Perraki, M., Kafousi, M., Apostolaki, S., Bolonaki, I., Stathopoulou, A., Kalbakis, K., Androulakis, N., Kouroussis, C., Pallis, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5948 · Cited by 263
Dai, H., van't Veer, L., Lamb, J., He, Y. D., Mao, M., Fine, B. M., Bernards, R., van de Vijver, M., Deutsch, P., Sachs, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3953 · Cited by 257
Proteomics of human breast ductal carcinoma in situ.
Wulfkuhle, J. D., Sgroi, D. C., Krutzsch, H. C., McLean, K. C., McGarvey, K. M., Knowlton, M., Chen, S., Shu, H., Şahin, A. A., Kurek, R., et al. (2002) · PubMed · Cited by 256
McTiernan, A., Martin, C. F., Peck, J. D., Aragaki, A. K., Chlebowski, R. T., Pisano, E. D., Wang, C. Y., Brunner, R. L., Johnson, K. C., Manson, J. E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji279 · Cited by 254
Lipton, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1467 · Cited by 253
The HOXB13:IL17BR Expression Index Is a Prognostic Factor in Early-Stage Breast Cancer
Ma, X.-J., Hilsenbeck, S. G., Wang, W., Ding, L., Sgroi, D. C., Bender, R. A., Osborne, C. K., Allred, D. C., & Erlander, M. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6944 · Cited by 252
Consensus conference on the classification of ductal carcinoma in Situ
(1997) · Cancer · Cited by 245
Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hösch, S., & Hayes, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2518 · Cited by 239
Self-citationDuffy, M. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1194 · Cited by 229
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., & Miles, D. W. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690196 · Cited by 220
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Kramer, M. D., Jänicke, F., & Klijn, J. G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1648 · Cited by 219
Eppenberger, U., Kueng, W., Schlaeppi, J. M., Roesel, J. L., Benz, C., Mueller, H., Matter, A., Zuber, M., Luescher, K., Litschgi, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.3129 · Cited by 218
Funke, I., & Schraut, W. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.557 · Cited by 217
Drake, R. R., Schwegler, E. E., Malik, G., Diaz, J., Block, T., Mehta, A., & Semmes, O. J. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600176-mcp200 · Cited by 216
Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis
Jacquemier, J., Ginestier, C., Rougemont, J., Bardou, V.-J., Charafe-Jauffret, E., Geneix, J., Adélaïde, J., Koki, A., Houvenaeghel, G., Hassoun, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.767.65.3 · Cited by 215
Silverstein, M. J., Barth, A., Poller, D. N., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00283-o · Cited by 215
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
Ebeling, F. G., Stieber, P., Untch, M., Nagel, D., Konecny, G. E., Schmitt, U. M., Fateh-Moghadam, A., & Seidel, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600248 · Cited by 215
Braun, S., Schlimok, G., Heumos, I., Schaller, G., Riethdorf, L., Riethmüller, G., & Pantel, K. (2001) · PubMed · Cited by 212
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
Foekens, J. A., Look, M. P., Vries, J. B.-D., Gelder, M. E. M.-V., Putten, W. L. J. V., & Klijn, J. G. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690048 · Cited by 209
Adam, P. J., Boyd, R., Tyson, K. L., Fletcher, G. C., Stamps, A., Hudson, L., Poyser, H. R., Redpath, N., Griffiths, M., Steers, G., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210184200 · Cited by 208
Joensuu, H., Isola, J. J., Lundin, M., Salminen, T. M., Holli, K., Kataja, V. V., Pylkkänen, L. H., Turpeenniemi-Hujanen, T. M., von Smitten, K., & Lundin, J. E. (2003) · PubMed · Cited by 207
Makretsov, N. A., Huntsman, D. G., Nielsen, T. O., Yorida, E., Peacock, M., Cheang, M. C. U., Dunn, S. E., Hayes, M., van de Rijn, M., Bajdik, C., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0429 · Cited by 202
Zabrecky, J. R., Lam, T., McKenzie, S. J., & Carney, W. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52354-1 · Cited by 201
Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms
Porter, D. C., Zhang, N., Danes, C., McGahren, M. J., Harwell, R. M., Faruki, S., & Keyomarsi, K. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6254-6269.2001 · Cited by 194
Harbeck, N., Kates, R. E., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Krüger, A., Kiechle, M. B., Jänicke, F., Schmitt, M., & Foekens, J. A. (2002) · PubMed · Cited by 191
Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P., & Aaronson, S. A. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.12.5570 · Cited by 186
High‐throughput proteomic analysis of human infiltrating ductal carcinoma of the breast
Somiari, R. I., Sullivan, A., Russell, S., Somiari, S., Hu, H., Jordan, R., George, A., Katenhusen, R., Buchowiecka, A., Arciero, C., et al. (2003) · PROTEOMICS · doi:10.1002/pmic.200300560 · Cited by 186
Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3471 · Cited by 180
Self-citationProteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid
Alexander, H., Stegner, A. L., Wagner-Mann, C., Du Bois, G. C., Alexander, S., & Sauter, E. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1002 · Cited by 175
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
Berns, E. M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., Portengen, H., & Klijn, J. G. M. (1995) · Gene · doi:10.1016/0378-1119(94)00534-y · Cited by 173
Fung, E. T., Yip, T., Lomas, L., Wang, Z., Yip, C., Meng, X., Lin, S., Zhang, F., Zhang, Z., Chan, D. W., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20928 · Cited by 173
Goetz, M. P., Suman, V. J., Ingle, J. N., Nibbe, A. M., Visscher, D. W., Reynolds, C. A., Lingle, W. L., Erlander, M., Ma, X.-J., Sgroi, D. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1263 · Cited by 170
Smith, B., Slade, M. J., English, J., Graham, H., Lüchtenborg, M., Sinnett, H. D., Cross, N. C. P., & Coombes, R. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1432 · Cited by 168
Esteva, F. J., Sahin, A. A., Cristofanilli, M., Coombes, K., Lee, S.-J., Baker, J., Cronin, M., Walker, M., Watson, D., Shak, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1707 · Cited by 168
Linderholm, B., Lindh, B., Tavelin, B., Grankvist, K., & Henriksson, R. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000120)89:1<51::aid-ijc9>3.0.co;2-8 · Cited by 158
Gong, Y., Booser, D. J., & Sneige, N. (2005) · Cancer · doi:10.1002/cncr.20987 · Cited by 158
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
Baselga, J. M., Seidman, A. D., Rosen, P. P., & Norton, L. (1997) · PubMed · Cited by 157
Self-citationBouchet, C., Spyratos, F., Martin, P., Hacène, K., Gentile, A., & Oglobine, J. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.74 · Cited by 156
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
Konecny, G., Thomssen, C., Lück, H., Untch, M., Wang, H.-J., Kuhn, W. C., Eidtmann, H., Bois, A. D., Olbricht, S., Steinfeld, D., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh198 · Cited by 156
Harris, L. N., Broadwater, G., Lin, N., Miron, A., Schnitt, S. J., Cowan, D., Lara, J. F., Bleiweiss, I. J., Berry, D. A., Ellis, M. J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1622 · Cited by 154
Self-citationMénard, S., Valagussa, P., Pilotti, S., Gianni, L., Biganzoli, E. M., Boracchi, P., Tomasic, G., Casalini, P., Marubini, E., COLNAGHI, M. I., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.329 · Cited by 149
Cuny, M., Kramar, A., Courjal, F., Johannsdottir, V., Iacopetta, B. J., Fontaine, H., Grenier, J., Culine, S., & Theillet, C. G. (2000) · PubMed · Cited by 148
Taback, B., Chan, A. D., Kuo, C. T., Bostick, P. J., Wang, H.-J., Giuliano, A. E., & Hoon, D. S. �. (2001) · PubMed · Cited by 147
A Novel Approach Toward Development of a Rapid Blood Test for Breast Cancer
Vlahou, A., Laronga, C., Wilson, L., Gregory, B. W., Fournier, K. F., McGaughey, D. S., Perry, R. R., Wright, G. L., & Semmes, O. J. (2003) · Clinical Breast Cancer · doi:10.1016/s1526-8209(11)70627-9 · Cited by 146
Pawlik, T. M., Hawke, D. H., Liu, Y., Krishnamurthy, S., Fritsche, H. A., Hunt, K. K., & Kuerer, H. M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-68 · Cited by 142
Self-citationYang, Z., Harris, L. N., Palmer-Toy, D. E., & Hancock, W. S. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.065862 · Cited by 142
Self-citation(1990) · PubMed · Cited by 142
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
Carlson, R. W., Brown, E., Burstein, H. J., Gradishar, W. J., Hudis, C. A., Loprinzi, C. L., Mamounas, E. P., Perez, E. A., Pritchard, K. I., Ravdin, P. M., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2001 · Cited by 140
Self-citationGaforio, J. J., Serrano, M. J., Sánchez‐Rovira, P., Sirvent, A., Delgado‐Rodríguez, M., Campos, M., de la Torre, N., Algarra, I., Dueñas, R., & Lozano, A. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11479 · Cited by 133
Jansen, M. P. H. M., Sieuwerts, A. M., Look, M. P., Ruigrok-Ritstier, K., Gelder, M. E. M., van Staveren, I. L., Klijn, J. G. M., Foekens, J. A., & Berns, E. M. J. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3676 · Cited by 129
Estrogen Receptor Analysis for Breast Cancer
Diaz, L. K., & Sneige, N. (2005) · Advances in Anatomic Pathology · doi:10.1097/00125480-200501000-00003 · Cited by 127
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri‐Ross, H. A., Brady, C., Wyld, P. J., & Carney, W. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.098 · Cited by 124
Liu, S., Edgerton, S. M., Moore, D. H., & Thor, A. D. (2001) · PubMed · Cited by 122
川上, 雅., & 佐治, 重. (2005) · Mebio oncology · Cited by 112
Grünewald, K., Haun, M., Urbanek, M., Fiegl, M., Müller‐Holzner, E., Gunsilius, E., Dünser, M., Marth, C., & Gastl, G. A. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780112 · Cited by 112
Goffin, J. R., Chappuis, P. O., Bégin, L. R., Wong, N., Brunet, J., Hamel, N., Paradis, A.-J., Boyd, J. A., & Foulkes, W. D. (2003) · Cancer · doi:10.1002/cncr.11080 · Cited by 111
Pawlik, T. M., Fritsche, H. A., Coombes, K. R., Xiao, L., Krishnamurthy, S., Hunt, K. K., Pusztai, L., Chen, J.-N., Clarke, C. H., Arun, B., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1710-4 · Cited by 108
Self-citationBloomston, M., Zhou, J. X., Rosemurgy, A. S., Frankel, W. L., Muro‐Cacho, C., & Yeatman, T. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3659 · Cited by 106
Proteomic analysis of nipple aspirate fluid using SELDI‐TOF‐MS
Sauter, E. R., Shan, S., Hewett, J. E., Speckman, P. L., & Bois, G. C. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20742 · Cited by 101
HER2 Overexpression and Doxorubicin in Adjuvant Chemotherapy for Resectable Breast Cancer
Moliterni, A., Ménard, S., Valagussa, P., Biganzoli, E. M., Boracchi, P., Balsari, A., Casalini, P., Tomasic, G., Marubini, E., Pilotti, S., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.021 · Cited by 99
Bull, S. B., Özçelik, H., Pinnaduwage, D., Blackstein, M. E., Sutherland, D. A. J., Pritchard, K. I., Tzontcheva, A., Sidlofsky, S., Hanna, W. M., Qizilbash, A. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.128 · Cited by 99
Harris, L. N., Liotcheva, V. B., Broadwater, G., Ramirez, M. J., Maimonis, P. J., Anderson, S., Everett, T., Harpole, D. H., Moore, M. B., Berry, D. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1698 · Cited by 96
Self-citationSELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer
Hu, Y., Zhang, S., Yu, J., Liu, J., & Zheng, S. S. (2005) · The Breast · doi:10.1016/j.breast.2005.01.008 · Cited by 95
Baker, M. K., Mikhitarian, K., Osta, W. A., Callahan, K., Hoda, R. S., Brescia, F., Hall, R. K., Mitas, M., Cole, D. J., & Gillanders, W. E. (2003) · PubMed · Cited by 90
Sieuwerts, A. M., Look, M. P., Gelder, M. E. M., Timmermans, M. A. M., Trapman-Jansen, A., Garcia, R. R., Arnold, M., Goedheer, A. J. W., de Weerd, V., Portengen, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0225 · Cited by 90
Becker, S. M., Cazares, L. H., Watson, P. A., Lynch, H. T., Semmes, O. J., Drake, R. R., & Laronga, C. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.03.557 · Cited by 87
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients
Weigelt, B., Bosma, A. J., Hart, A. A. M., Rodenhuis, S., & Veer, L. J. V. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600868 · Cited by 85
Overgaard, J. (2000) · Acta Oncologica · doi:10.1080/028418600750013096 · Cited by 85
Kumpulainen, E., Keskikuru, R., & Johansson, R. T. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020514925143 · Cited by 80
Mano, M. S., Rosa, D. D., de Azambuja, E., Ismael, G., & Durbecq, V. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.10.001 · Cited by 76
Malmström, P., Bendahl, P.-O., Boiesen, P., Brünner, N., Idvall, I., & Fernö, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.7.2010 · Cited by 75
Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game
Gion, M., Boracchi, P., Dittadi, R., Biganzoli, E. M., Peloso, L., Mione, R., Gatti, C., Paccagnella, A., & Marubini, E. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00426-9 · Cited by 73
The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27
Wingate, H. F., Zhang, N., McGarhen, M. J., Bedrosian, I., Harper, J. W., & Keyomarsi, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409789200 · Cited by 72
Porter, P. L., Barlow, W. E., Yeh, I., Lin, M. G., Yuan, X., Donato, E., Sledge, G. W., Shapiro, C. L., Ingle, J. N., Haskell, C. M., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj467 · Cited by 72
Self-citationEspinosa, E., Vara, J. Á. F., Redondo, A., Sánchez, J. J., Hardisson, D., Zamora, P. M., Gómez-Pastrana, F., Cejas, P., Martínez, B., Suárez, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4746 · Cited by 70
Mehta, R., McDermott, J. H., Hieken, T. J., Marler, K. C., Patel, M. K., Wild, L., & Gupta, T. K. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2409 · Cited by 64
Nicolini, A., Tartarelli, G., Carpi, A., Metelli, M. R., Ferrari, P., Anselmi, L., Conte, M., Berti, P., & Miccoli, P. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-269 · Cited by 63
Dissemination Risk Index Based on Plasminogen Activator System Components in Primary Breast Cancer
Bouchet, C., Hacène, K., Martin, P., Becette, V., Tubiana-Hulin, M., Lasry, S., Oglobine, J., & Spyratos, F. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3048 · Cited by 61
Lauro, S. D., Trasatti, L., Bordin, F., Lanzetta, G., Bria, E., Gelibter, A. J., Reale, M. G., & Vecchione, A. M. (1999) · PubMed · Cited by 56
Pinto, A. E., André, S., & Soares, J. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.8.604 · Cited by 55
Historical perspective on hormonal therapy of advanced breast cancer
JORDAN, C. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85031-7 · Cited by 51
Proteomics: Recent Applications and New Technologies
Elrick, M. M., Walgren, J., Mitchell, M. D., & Thompson, D. C. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_391.x · Cited by 49
Cyclin E Expression and Prognosis in Breast Cancer Patients: A Meta-Analysis of Published Studies
Wang, L., & Shao, Z. (2006) · Cancer Investigation · doi:10.1080/07357900600894799 · Cited by 41
Rudolph, P., Alm, P., Olsson, H. L., Heidebrecht, H.-J., Fernö, M., Baldetorp, B., & Parwaresch, R. M. (2001) · Human Pathology · doi:10.1053/hupa.2001.22748 · Cited by 41
Gene-expression profiling in breast cancer
Jenssen, T.-K., & Hovig, E. J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70911-9 · Cited by 40
Gebauer, G., Fehm, T. N., Merkle, E., Jaeger, W., & Mitze, M. (2003) · PubMed · Cited by 34
Proteomic phenotyping: metastatic and invasive breast cancer
Hathout, Y., Gehrmann, M. L., Chertov, A. O., & Fenselau, C. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.01.019 · Cited by 34
Cekaite, L., Hovig, E. J., & Sioud, M. (2006) · Humana Press eBooks · doi:10.1385/1-59745-165-7:335 · Cited by 26
Gion, M., Boracchi, P., Dittadi, R., Biganzoli, E. M., Peloso, L., Gatti, C., Paccagnella, A., Rosabian, A., Vinante, O., & Meo, S. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006318112776 · Cited by 22
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
Lipton, A., Mouridsen, H. T., Ali, S.-A. M., et al. (2001) · Breast Diseases A Year Book Quarterly · Cited by 22
Assessment of CA 15.3, CEA and TPA Concentrations during Monitoring of Breast Cancer
Sölétormos, G., Petersen, P. H., & Dombernowsky, P. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.066 · Cited by 17
Cited by
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Self-citationGyörffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
(2012) · doi:10.1016/j.jmoldx.2011.08.002 · Cited by 2,567
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Self-citation
Metadata
- Authors
- Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-11-20
- Volume
- 25
- Issue
- 33
- Pages
- 5287-5312
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2117305280
- Cited by
- 2,217
- References
- 185
- FWCI
- 50.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.